尼妥珠单抗联合适形放疗及化疗治疗局部晚期鼻咽癌的临床应用效果观察

发布时间：2018-04-01 03:33

本文选题：尼妥珠单克隆抗体　切入点：适形放疗　出处：《药品评价》2016年21期

【摘要】：目的:探究针对局部性晚期鼻咽癌患者行尼妥珠单克隆抗体联合同期性适形放疗和紫杉醇铂剂药物化疗的临床效果。方法:择取2012年2月至2015年1月赣南医学院第一附属医院收治的局部性晚期鼻咽癌患者122例作为本次研究对象,按照患者的入院时间先后顺序随机将其等分为研究组和参照组,每组各包含61例患者,参照组患者行三维适形放疗或调强适形放疗,以及序贯紫杉醇铂剂药物化疗,研究组患者在适形放疗和药物化疗基础上,于化疗前静脉滴注100mg尼妥珠单克隆抗体,观察比较两组患者的治疗效果,急性不良反应和远期不良反应发生状况。结果:研究组患者的放疗后2个月原发灶完全缓解率、颈部淋巴结完全缓解率以及总评价、治疗后1年局部控制率、无转移生存率以及总评价均显著高于参照组,组间数据差异具有统计学意义(P0.05)。研究组患者的急性不良反应发生状况和远期不良反应发生状况与参照组患者大致相当。组间数据差异不具有统计学意义(P0.05)。结论:在适形放疗和序贯药物放疗基础上实施尼妥珠单克隆抗体静脉滴注治疗,尽管不能显著影响患者的不良反应发生状况,但却能够显著改善患者的治疗有效率和病情控制效果,优化患者在患病和接受治疗过程中的生存质量,值得在临床医学实践过程中予以推广运用。
[Abstract]:Objective: to investigate the clinical effect of Nitozhu monoclonal antibody combined with conformal radiotherapy and paclitaxel platinum drug chemotherapy in patients with locally advanced nasopharyngeal carcinoma. Methods: from February 2012 to January 2015, Gannan Medical College was selected. 122 patients with locally advanced nasopharyngeal carcinoma treated in the first affiliated Hospital were selected as the subjects of this study. The patients were randomly divided into study group and reference group according to their admission time. Each group consisted of 61 patients. The control group received three-dimensional conformal radiotherapy or intensity modulated conformal radiotherapy, as well as sequential paclitaxel platinum drug chemotherapy. On the basis of conformal radiotherapy and drug chemotherapy, the patients in the study group were treated by intravenous infusion of 100mg Nitov monoclonal antibody before chemotherapy, and the therapeutic effects of the two groups were observed and compared. Results: the complete remission rate of primary focus, the complete remission rate of cervical lymph nodes and the total evaluation of the patients in the study group were observed 2 months after radiotherapy, and the local control rate was 1 year after treatment. The metastasis-free survival rate and overall evaluation were significantly higher than those in the control group. The incidence of acute adverse reactions and the occurrence of long-term adverse reactions in the study group were similar to those in the control group, but there was no significant difference in the data between the two groups (P 0.05). Conclusion:. On the basis of conformal radiotherapy and sequential drug radiotherapy, intravenous infusion of Monoclonal Antibody (McAb) was performed. Although it could not significantly affect the occurrence of adverse reactions in patients, it could significantly improve the effective rate of treatment and the effect of disease control, and optimize the quality of life of patients during the course of illness and treatment. It is worth popularizing and applying in clinical practice.
【作者单位】：赣南医学院第一附属医院肿瘤科;
【分类号】：R739.63

【参考文献】